Immunotherapy After Chemoradiation Improves Survival in Stage III NSCLC - Cancer Therapy Advisor
Immunotherapy after chemotherapy and radiation provides a survival benefit for patients with unresectable, stage III non-small cell lung cancer (NSCLC), according to real-world data published in JAMA Network Open . Researchers noted that the PACIFIC trial (ClinicalTrials.gov Identifier: NCT02125461) established a role for the use of immunotherapy after chemoradiation in this patient population. However, the general population of patients with unresectable, stage III NSCLC in the United States may differ from patients enrolled in the PACIFIC trial. Continue Reading To assess real-world outcomes of immunotherapy after chemoradiation, the researchers analyzed data from the National Cancer Database. The analysis included 23,811 patients who were newly diagnosed with unresectable, stage III NSCLC between 2015 and 2017. The median age at baseline was 66 (range, 59-72) years, 43.9% of patients were women, and 84....